SOD1 and amyotrophic lateral sclerosis: The first demonstration of a therapeutic potential in ALS was a 20-nucleotide ASO-targeting SOD1. Intra-cerebroventricular injections of this ASO in mutant SOD1 rats resulted in the reduction of SOD1 mRNA and protein levels throughout the brain and spinal cord and slowed disease progression25.